The SP-X™ imaging and analysis system

 
INTRODUCING THE NEW SP-X™ IMAGING AND ANALYSIS SYSTEM

Featuring Simoa® Planar Technology
Multiplex up to 10 analytes at ultra-low, even baseline, levels

Learn More about the New SP-X!

We are on a mission to change the way in which healthcare is provided by giving researchers the ability to closely examine the continuum from health to disease. Click on one of the therapeutic category icons below to learn how our revolutionary technology is helping researchers advance the science of precision health.

oncology
Oncology

​​​​​​The ability to detect oncology biomarkers at ultra-low levels is enabling new options for diagnostics and treatment in cancer research. Simoa assays can be used to monitor cancer risk, identify early stage cancers and discriminate between benign and malignant cells. Simoa biomarkers can be used prognostically to predict disease outcome, predict progression free survival and monitor reoccurrence. Assays can also be used to monitor sensitivity to therapy and to aid in treatment decisions.

neurology
Neurology

The ability to detect neurological biomarkers at ultra-low levels, which have traditionally only been detectable in cerebrospinal fluid, will transform the way brain injuries and diseases are diagnosed. Simoa assays can detect biomarkers associated with brain injury and disease at much earlier stages to understand the long-term effects and disease pathology. Quanterix has a strategic focus in neurology and neurodegeneration and is working with a rapidly growing network of academic researchers and pharmaceutical and biotech partners to drive advancements in head health research.

cardiology
Cardiology

The ability to detect cardiac biomarkers at ultra-low levels is advancing the future of heart health. Simoa assays can detect cardiac biomarkers, which are instrumental for predicting major adverse cardiovascular events, development of heart failure or transition to end-stage kidney disease, earlier than ever before. Further, the ability to detect minute changes in these biomarkers enables the identification of at-risk patients earlier in their disease progression to guide more personalized, preventive care. 

Inflammatory
Immunology

Simoa assays can measure inflammatory and anti-inflammatory molecules in serum and plasma with unprecedented sensitivity enabling new discoveries into the role of inflammation in the biology of health and disease.  The ability to measure the cascade of events leading to inflammation at the earliest stage of disease progression or treatment response will enable researchers to make new insights into prevention and treatment of inflammation in multiple therapeutic areas.

Infectious Disease
Infectious Disease

The ability to detect infectious disease biomarkers before the onset of an immune response, while a virus is most contagious and multiplying rapidly, is critical for controlling the spread of disease. Infectious disease is one of the hottest areas of research today and researchers continue to seek ways to detect and diagnose infections earlier and more accurately. Simoa assays can have a significant impact in reducing the spread of the disease by making early stage detection more widely available.

Bloomberg Radio Interview
September 25, 2018

In a recent interview with Baystate Business, Quanterix Chairman and CEO and founder of Powering Precision Health, Kevin Hrusovsky explains the fundamentals of Quanterix technology and how it's disrupting the way healthcare is practiced. 

 

 

WEBINAR: September 19, 2018
Disrupting Drug Development with Biomarkers and the Power of Precision Health

This presentation contains “forward-looking” statements that are based on our beliefs and assumptions and on information available to us as of the date of this presentation. Forward-looking statements include all statements that are not historical facts. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The risks and uncertainties that we face are described in our most recent filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

Digital Biotech Podcast
Interview with Kevin Hrusovsky, Chairman and CEO of Quanterix

Kevin Hrusovsky, Quanterix Chairman and CEO and Founder of Powering Precision Health, recently sat down with TetraScience CEO Alok Tayi to talk about the exciting work that Quanterix is doing in the area of clinical biomarkers and the business of diagnostics as well as a broader view of healthcare in the United States.

Listen to the podcast here!

Simoa Bead Technology
Watch our one minute video

Quanterix' proprietary Simoa Bead Technology is based on the isolation of individual immunocomplexes on paramagnetic beads using standard ELISA reagents.

 

Learn More About Our Technology
A Message From Kevin Hrusovsky
President, CEO & Chairman of Quanterix

We're passionate about the work we do and believe we can transform today’s sick care into tomorrow’s precision healthcare. The future of healthy living is being realized by uncovering novel biomarkers with the power to transform medicine, allowing for prevention, early diagnosis and nextgen treatments. 

Report by Dr. Mallika Marshall

CBS Boston

According to the Centers for Disease Control, up to four million concussions occur each year. A big challenge is trying to figure out whether someone has actually had one or not. Lexington-based Quanterix may have a solution.

“It’s like rocket science on the blood,” says Quanterix CEO and Executive Chairman, Kevin Hrusovsky.

Read the full report on boston.cbslocal.com

Panel Discussion
Early Diagnosis Through Predictive Biomarkers, NonInvasive Testing

In an excerpt from a panel discussion which took place at MedCity CONVERGE on July 11, 2018, Quanterix Chairman and CEO Kevin Hrusovsky joins other key innovators to discuss game-changing biotech advancements and the future of healthcare.

Neurology Interactive Toolkit
Explore critical biomarkers in the detection of brain injury and neurodegenerative disease
START EXPLORING
Simoa Planar Technology

Watch how our new planar technology and the elegant simplicity of the new SP-X Imaging and Analysis system enable ultra-sensitive biomarker detection of up to 10 analytes per sample.

Click Here to Get Our Latest News